Design Therapeutics, Inc.
DSGN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DSGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DSGN
Design Therapeutics, Inc. is a biotechnology company focused on developing treatments for serious degenerative disorders, with no approved products and a net loss of $20.2M for the quarter ended June 30, 2026.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials · 1 catalyst for Design Therapeutics, Inc..
Design Therapeutics, Inc. is a biotechnology company focused on developing treatments for serious degenerative disorders, with no approved products and a net loss of $20.2M for the quarter ended June 30, 2026.
- Cash & equivalents of $12.9M as of 2026-06-30 [sec].
- Total revenue of $0.0M for the quarter ended 2026-06-30 [sec].
- Net loss of $20.2M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $212.5M as of 2026-06-30 [sec].
- Upcoming Phase 3 topline data for generic drugs (Dapagliflozin and Saxagliptin) in Type 2 diabetes patients with controlled cancers expected on 2026-11-28 [catalyst].
What works
- Shareholders' equity of $212.5M provides a substantial capital base to fund operations and clinical development as of 2026-06-30 [sec].
- The company has a defined catalyst with a Phase 3 topline readout scheduled for November 2026, which could provide clarity on the program's prospects [catalyst].
What to weigh
- Cash & equivalents of only $12.9M as of 2026-06-30 may be insufficient to fund operations for an extended period without additional financing [sec].
- The company has no revenue and reported a net loss of $20.2M for the quarter ended 2026-06-30, indicating ongoing cash burn [sec].
- Clinical trial costs are uncertain and could require more capital than anticipated, as noted in SEC filings [sec_mda].
Catalyst timeline
- 2026-11-28 · Phase3_Topline — Phase 3 Topline: Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers — The topline readout will provide initial efficacy and safety data for the Phase 3 trial of these generic drugs in the specified patient population.
Risks & what to watch (3)›
Key risks
- Cash runway uncertainty — Cash & equivalents of $12.9M as of 2026-06-30 may be insufficient to fund operations without additional financing [sec].
- No revenue and ongoing losses — The company has no revenue and reported a net loss of $20.2M for the quarter ended 2026-06-30 [sec].
- Clinical trial cost variability — Clinical trial costs are uncertain and could require more capital than anticipated [sec_mda].
What to watch
- Phase 3 topline data for generic drugs (Dapagliflozin and Saxagliptin) in Type 2 diabetes patients with controlled cancers expected on 2026-11-28 [catalyst].
- Cash burn rate and any updates on financing or capital management in upcoming SEC filings [sec_mda].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Design Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Design Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
38.5 months
D/E 0.07 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~90d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
120
Total value held
$267.2M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 2,972,973 | $31.6M |
| vanguard capital management llc | 2,699,700 | $28.7M |
| baker bros. advisors lp | 2,585,978 | $27.5M |
| blackrock, inc. | 2,133,764 | $22.7M |
| woodline partners lp | 1,923,002 | $20.5M |
| driehaus capital management llc | 1,744,987 | $18.6M |
| trails edge capital partners, lp | 852,013 | $9.1M |
| fmr llc | 798,411 | $8.5M |
| kynam capital management, lp | 784,606 | $8.3M |
| geode capital management, llc | 692,518 | $7.4M |
Showing top 10 of 120 institutional holders of Design Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 4.8%
- Days to cover
- 6.7
- Shares short
- 2,238,096
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DSGN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Design Therapeutics, Inc.?
Design Therapeutics, Inc. is a biotechnology company focused on developing treatments for serious degenerative disorders, with no approved products and a net loss of $20.2M for the quarter ended June 30, 2026.
What is Design Therapeutics, Inc.'s next catalyst?
Design Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers" — expected November 28, 2026.
Who is the CEO of Design Therapeutics, Inc.?
Mr. Pratik Shah Ph.D. is the chief executive officer of Design Therapeutics, Inc. (DSGN).
Where is Design Therapeutics, Inc. headquartered?
Design Therapeutics, Inc. (DSGN) is headquartered in Carlsbad, CA, United States.
What therapeutic areas does Design Therapeutics, Inc. focus on?
Design Therapeutics, Inc. develops therapies across Oncology, Rare Disease, Neurology, Ophthalmology, Respiratory, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.